120 related articles for article (PubMed ID: 24745065)
1. Pharmacokinetics and preliminary safety data of a single oral dose of bosentan, a dual endothelin receptor antagonist, in cats.
Puza N; Papich MG; Reinero C; Chang CH; Yu DH; Sharp C; DeClue A
J Vet Pharmacol Ther; 2014 Apr; 37(2):192-5. PubMed ID: 24745065
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.
Dingemanse J; van Giersbergen PL
Clin Pharmacokinet; 2004; 43(15):1089-115. PubMed ID: 15568889
[TBL] [Abstract][Full Text] [Related]
3. Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers.
Weber C; Schmitt R; Birnboeck H; Hopfgartner G; Eggers H; Meyer J; van Marle S; Viischer HW; Jonkman JH
J Clin Pharmacol; 1999 Jul; 39(7):703-14. PubMed ID: 10392325
[TBL] [Abstract][Full Text] [Related]
4. Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects.
Weber C; Gasser R; Hopfgartner G
Drug Metab Dispos; 1999 Jul; 27(7):810-5. PubMed ID: 10383925
[TBL] [Abstract][Full Text] [Related]
5. Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole.
van Giersbergen PL; Halabi A; Dingemanse J
Br J Clin Pharmacol; 2002 Jun; 53(6):589-95. PubMed ID: 12047483
[TBL] [Abstract][Full Text] [Related]
6. Relative bioavailability of a newly developed pediatric formulation of bosentan vs. the adult formulation.
Gutierrez MM; Nicolas LB; Donazzolo Y; Dingemanse J
Int J Clin Pharmacol Ther; 2013 Jun; 51(6):529-36. PubMed ID: 23611572
[TBL] [Abstract][Full Text] [Related]
7. Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist.
Dingemanse J; van Giersbergen PL
Int J Clin Pharmacol Ther; 2002 Jul; 40(7):310-6. PubMed ID: 12139208
[TBL] [Abstract][Full Text] [Related]
8. Bosentan for the treatment of pulmonary arterial hypertension.
Kenyon KW; Nappi JM
Ann Pharmacother; 2003; 37(7-8):1055-62. PubMed ID: 12841819
[TBL] [Abstract][Full Text] [Related]
9. Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist.
Dingemanse J; Bodin F; Weidekamm E; Kutz K; van Giersbergen P
J Clin Pharmacol; 2002 Mar; 42(3):283-9. PubMed ID: 11865964
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.
Wrishko RE; Dingemanse J; Yu A; Darstein C; Phillips DL; Mitchell MI
J Clin Pharmacol; 2008 May; 48(5):610-8. PubMed ID: 18305126
[TBL] [Abstract][Full Text] [Related]
11. A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE-3.
Berger RMF; Gehin M; Beghetti M; Ivy D; Kusic-Pajic A; Cornelisse P; Grill S; Bonnet D;
Br J Clin Pharmacol; 2017 Aug; 83(8):1734-1744. PubMed ID: 28213957
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension.
Barst RJ; Ivy D; Dingemanse J; Widlitz A; Schmitt K; Doran A; Bingaman D; Nguyen N; Gaitonde M; van Giersbergen PL
Clin Pharmacol Ther; 2003 Apr; 73(4):372-82. PubMed ID: 12709727
[TBL] [Abstract][Full Text] [Related]
13. Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin.
Dingemanse J; Schaarschmidt D; van Giersbergen PL
Clin Pharmacokinet; 2003; 42(3):293-301. PubMed ID: 12603176
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects.
Weber C; Schmitt R; Birnboeck H; Hopfgartner G; van Marle SP; Peeters PA; Jonkman JH; Jones CR
Clin Pharmacol Ther; 1996 Aug; 60(2):124-37. PubMed ID: 8823230
[TBL] [Abstract][Full Text] [Related]
15. Disposition of deracoxib in cats after oral administration.
Gassel AD; Tobias KM; Cox SK
J Am Anim Hosp Assoc; 2006; 42(3):212-7. PubMed ID: 16611933
[TBL] [Abstract][Full Text] [Related]
16. Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers.
Gotzkowsky SK; Dingemanse J; Lai A; Mottola D; Laliberte K
J Clin Pharmacol; 2010 Jul; 50(7):829-34. PubMed ID: 20133511
[TBL] [Abstract][Full Text] [Related]
17. Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension.
Dhillon S; Keating GM
Am J Cardiovasc Drugs; 2009; 9(5):331-50. PubMed ID: 19791841
[TBL] [Abstract][Full Text] [Related]
18. Bosentan.
Chin K; Channick R
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):175-82. PubMed ID: 15151466
[TBL] [Abstract][Full Text] [Related]
19. Mutual pharmacokinetic interactions between bosentan and lopinavir/ritonavir in healthy participants.
Dingemanse J; van Giersbergen PL; Patat A; Nilsson PN
Antivir Ther; 2010; 15(2):157-63. PubMed ID: 20386070
[TBL] [Abstract][Full Text] [Related]
20. Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin.
Weber C; Banken L; Birnboeck H; Schulz R
J Clin Pharmacol; 1999 Aug; 39(8):847-54. PubMed ID: 10434238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
